Study of new drug with osimertinib for advanced EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug (SYS6010) combined with an existing targeted therapy (osimertinib) for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than standard treatments and to find a safe dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have non-small cell lung cancer (NSCLC) that is advanced or has spread, and you have a specific EGFR gene change (exon 19 deletion or L858R).
- For the main part of the trial, you have not had any prior EGFR-targeted therapy or other cancer medications for advanced disease.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are generally able to take care of yourself and carry out light activities (ECOG 0-1).
- You have not had certain serious health problems in the recent past, like heart disease, lung scarring (interstitial lung disease), or infections requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.